The Invasive Fungal Infections Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Invasive Fungal Infections Market:
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
According to The Business Research Company’s Invasive Fungal Infections Global Market Report 2024, The invasive fungal infections market size has grown strongly in recent years. It will grow from $7.21 billion in 2023 to $7.58 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to global spread of infections, hematopoietic stem cell transplants, aging population, hospital-acquired infections, environmental factors..
The invasive fungal infections market size is expected to see steady growth in the next few years. It will grow to $9.08 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to global health preparedness, public health education, novel antifungal agents, climate change impact, multidisciplinary approaches.. Major trends in the forecast period include advancements in diagnostic technologies, tailored therapeutic approaches, patient-centric care, combination antifungal therapies, collaborations for drug development..
The rise in the population suffering from human immunodeficiency virus (HIV) is expected to propel the growth of the invasive fungal infection market going forward. HIV (Human Immunodeficiency Virus) infection is a virus that compromises the immune system’s ability to defend against diseases and illnesses. The rising number of individuals with compromised immune systems, such as HIV (Human Immunodeficiency Virus) or AIDS (acquired immunodeficiency syndrome), increases the susceptibility to invasive fungal infections, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs. For instance, in July 2023, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), the Switzerland-based United Nations program dedicated to addressing the global HIV/AIDS epidemic, the global population living with HIV increased to 39 million in 2022, up 3.17% from 37.7 million in 2020. Furthermore, there were approximately 1.3 million new HIV infections reported in 2022. Therefore, the rise in the population suffering from the human immunodeficiency virus (HIV) will drive the growth of the invasive fungal infection market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp
The invasive fungal infections market covered in this report is segmented –
1) By Disease Type: Candidaemi And Invasive Candiasis, Intra Abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Type
2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Type
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Major companies operating in the invasive fungal infection market are focused on developing an antifungal drug such as Posaconazole to address the increasing demand for more effective and innovative treatments for fungal infections and gain a competitive edge in the market. Antifungal drugs such as Posaconazole are medications designed to treat fungal infections by inhibiting growth or killing the fungi responsible for the disease. For instance, in June 2021, Cadila Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Posaconazol, a new triazole antifungal drug. It is effective against various invasive fungal diseases and is recommended as a second-line treatment for mucormycosis (black fungus). This drug is approved to prevent aspergillus and candida infections in immunocompromised patients and treat oropharyngeal candidiasis (OPC).
The invasive fungal infections market report table of contents includes:
.
.
.
Top Major Players :
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The military truck market size is expected to see steady growth in the next few…
Overview and Scope Artificial intelligence software as a service (SaaS) is a cloud-based service that…
Overview and Scope An artificial intelligence or machine learning (AI/ML) medical device is a medical…
The data center low voltage (lv) or medium voltage (mv) power distribution market size is…
Overview and Scope Satellite-based earth observation refers to satellites orbiting around the Earth to view,…
Overview and Scope Personal watercraft refers to a vessel designed to be operated by a…